Filing Details

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )^*

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [   ].

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Section 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

Page 1 of 45 Pages

Exhibit Index Found on Page 36

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

13D

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

13D

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

¹ On August 2, 2023, the date of the event which requires the filing of this Statement, certain Reporting Persons acquired shares of common stock of the issuer, as a result of which the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the class of common stock then outstanding.  Rows 7 through 13 of the cover page for each Reporting Person report beneficial ownership of common stock acquired through August 10, 2023.  As described in the Preliminary Note and reported in Item 5(e), the issuer was acquired by Novartis AG on August 11, 2023.  Accordingly, as of the date this Statement is filed, none of the Reporting Persons is a beneficial owner of any shares of common stock of the issuer.

13D

On August 2, 2023, the Reporting Persons in the aggregate acquired beneficial ownership of more than 5% of the Shares then outstanding.  As reported by the Company on its Form 8-K filed with the SEC on August 11, 2023 (the “Company 8-K”), on such date the Company and Novartis AG (“Novartis”) closed their merger transaction (the “Novartis Merger”), as a result of which each outstanding Share was automatically converted into the right to receive the merger consideration described in the Company 8-K and the Company became a wholly-owned subsidiary of Novartis.  Accordingly, as of August 11, 2023, the Reporting Persons ceased to have beneficial ownership of any Shares.  See Item 5(e) below.  Capitalized terms used in this Preliminary Note without definitions have the meanings ascribed to them below.

Item 2.

Identity and Background

(i)	Farallon Capital Partners, L.P., a California limited partnership (“FCP”), with respect to the Shares held by it;

(ii)	Farallon Capital Institutional Partners, L.P., a California limited partnership (“FCIP”), with respect to the Shares held by it;

(iii)

Farallon Capital Institutional Partners II, L.P., a California limited partnership (“FCIP II”), with respect to the Shares held by it;

(iv)	Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership (“FCIP III”), with respect to the Shares held by it;

(v)	Four Crossings Institutional Partners V, L.P., a Delaware limited partnership (“FCIP V”), with respect to the Shares held by it;

(vi)	Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership (“FCOI II”), with respect to the Shares held by it;

(vii)

Farallon Capital (AM) Investors, L.P., a Delaware limited partnership (“FCAMI”), with respect to the Shares held by it; and

(viii)

Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership (“F5MI”), with respect to the Shares held by it.

FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI and F5MI are together referred to herein as the “Farallon Funds.”

(ix)

Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner”), which is (i) the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and (ii) the sole member of the FCIP V General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI.

(x)	Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the “FCIP V General Partner”), which is the general partner of FCIP V, with respect to the Shares held by FCIP V.

(xi)	Farallon F5 (GP), L.L.C., a Delaware limited liability company (the “F5MI General Partner”), which is the general partner of F5MI, with respect to the Shares held by F5MI.

(xii)

The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, with respect to the Shares held by the Farallon Funds: Joshua J. Dapice (“Dapice”); Philip D. Dreyfuss (“Dreyfuss”); Hannah E. Dunn (“Dunn”); Richard B. Fried (“Fried”); Varun N. Gehani (“Gehani”); Nicolas Giauque (“Giauque”); David T. Kim (“Kim”); Michael G. Linn (“Linn”); Rajiv A. Patel (“Patel”); Thomas G. Roberts, Jr. (“Roberts”); Edric C. Saito (“Saito”); William Seybold (“Seybold”); Daniel S. Short (“Short”); Andrew J. M. Spokes (“Spokes”); John R. Warren (“Warren”); and Mark C. Wehrly (“Wehrly”).

Dapice, Dreyfuss, Dunn, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the “Farallon Individual Reporting Persons.”

(b)       The address of the principal business office of (i) each of the Farallon Funds is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111, and (ii) each of the FCIP V General Partner, the F5MI General Partner and the Farallon Individual Reporting Persons is set forth in Annex 1 hereto.

(c)       The principal business of each of the Farallon Funds is that of a private investment entity engaging in the purchase and sale of investments for its own account. The principal business of the Farallon General Partner is to act as the general partner of investment partnerships, including FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and as the sole member of general partners of investment partnerships, including the FCIP V General Partner.  The principal business of the FCIP V General Partner is to act as the general partner of FCIP V.  The principal business of the F5MI General Partner is to act as the general partner of F5MI.  The principal business of each of the Farallon Individual Reporting Persons is set forth in Annex 1 hereto.

(d)       None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)       None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f)       The jurisdiction of organization of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner and the F5MI General Partner is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque and Spokes, is a citizen of the United States.  Giauque is a citizen of France.  Spokes is a citizen of the United Kingdom.

 

The other information required by Item 2 relating to the identity and background of the Reporting Persons is set forth in Annex 1 hereto.

The purpose of the acquisition of the Shares was for investment prior to and in anticipation of the Novartis Merger.  Other than disposing of all of the Reporting Persons’ Shares in the Novartis Merger, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

As reported in the Company 8-K, the Novartis Merger closed on August 11, 2023.  Accordingly, as of such date the Reporting Persons ceased to have beneficial ownership of any Shares.

Item 5. Interest in Securities of the Issuer

(c) None.

(e)

As reported in the Company 8-K, the Novartis Merger closed on August 11, 2023.  Accordingly, as of such date the Reporting Persons ceased to have beneficial ownership of any Shares.

(c) None.

(e)

As reported in the Company 8-K, the Novartis Merger closed on August 11, 2023.  Accordingly, as of such date the Reporting Persons ceased to have beneficial ownership of any Shares.

(a),(b)     The information set forth in Rows 7 through 13 of the cover page hereto for each Farallon Individual Reporting Person is incorporated herein by reference for each such Farallon Individual Reporting Person.

(e)

As reported in the Company 8-K, the Novartis Merger closed on August 11, 2023.  Accordingly, as of such date the Reporting Persons ceased to have beneficial ownership of any Shares.

The Shares reported hereby for the Farallon Funds are beneficially owned by the Farallon Funds. The Farallon General Partner, as general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner, may be deemed to be a beneficial owner of all such Shares beneficially owned by the Farallon Funds other than F5MI. The FCIP V General Partner, as general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares beneficially owned by FCIP V. The F5MI General Partner, as general partner of F5MI, may be deemed to be a beneficial owner of all such Shares beneficially owned by F5MI.  Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5MI General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares beneficially owned by the Farallon Funds.  Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.

Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Company, including but not limited to the transfer or voting of any securities of the Company, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

There is filed herewith as Exhibit 1 a written agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated:  August 11, 2023

The Powers of Attorney executed by each of Dapice, Dreyfuss, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly authorizing Dunn to sign and file this Schedule 13D on his behalf, which were filed as exhibits to the Schedule 13G filed with the SEC on January 31, 2023 by such Reporting Persons with respect to the Class A Ordinary Shares of ARYA Sciences Acquisition Corp IV, are hereby incorporated by reference.

ANNEX 1

Set forth below with respect to each of the Farallon General Partner, the FCIP V General Partner and the F5MI General Partner is the following information: (a) name; (b) business address; (c) principal business; (d) state of organization; and (e) controlling persons.  Set forth below with respect to each managing member of the Farallon General Partner is the following information: (a) name; (b) business address; (c) principal occupation; and (d) citizenship.

 

 

 

 

 

 

None of the Farallon General Partner and its Managing Members has any additional information to disclose with respect to Items 2-6 of this Schedule 13D that is not otherwise disclosed in this Schedule 13D.

EXHIBIT INDEX

1.	Joint Acquisition Statement Pursuant to Section 240.13d-1(k), dated August 11, 2023

EXHIBIT 1

to

SCHEDULE 13D

 

JOINT ACQUISITION STATEMENT

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

 

Dated: August 11, 2023

 

FARALLON CAPITAL PARTNERS, L.P.

FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.

FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.

FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.

FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.

FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.

FARALLON CAPITAL (AM) INVESTORS, L.P.

FARALLON CAPITAL F5 MASTER, L.P.